Impact of Coronavirus Disease 2019 Pandemic on Parkinson’s Disease: A Cross-Sectional Survey of 568 Spanish Patients

Diego Santos-García, MD, PhD,1* Mila Oreiro,2 Patricia Pérez,3 Gemma Fanjul,3 José Manuel Paz González,1 María José Feal Paineiras,1 Carlos Cores Bartolomé,1 Lorena Valdés Aymerich,1 Carlos García Sancho,1 and María del Mar Castellanos Rodrigo1

1Department of Neurology, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain 2Asociación Parkinson Galicia – Coruña, A Coruña, Spain 3Federación Española de Parkinson, Madrid, Spain

ABSTRACT: Background: The aim of this study was to know the impact of the coronavirus disease 2019 (COVID-19) pandemic on Spanish patients with Parkinson’s disease (PD).

Methods: This is a descriptive, observational, cross-sectional study. An anonymous online survey with 95 questions was distributed among patients. Responses were collected from 11 May 2020 to 20 July 2020.

Results: Of a total of 570 questionnaires received, 568 (99.6%) were considered valid for the analysis (mean age, 63.5 ± 12.5 years; 53% females). A total of 553 patients (97.4%) were aware of the COVID-19 pandemic and 68.8% were concerned about it; 95.6% took preventive measures. A total of 484 patients (85.2%) had no contact with cases of COVID-19, and only 15 (2.6%) had confirmed COVID-19. Although up to 72.7% remained active during confinement, 65.7% perceived a worsening of their symptoms.

Conclusions: Spanish patients with PD perceived the COVID-19 pandemic with concern and responsibility. More than half experienced worsening of their symptoms during confinement. © 2020 International Parkinson and Movement Disorder Society

Key Words: confinement; COVID-19; impact; pandemic; Parkinson’s disease

The coronavirus disease 2019 (COVID-19) pandemic has resulted in unprecedented disruptions involving every aspect of life across the globe.1 Governments have taken several measures, such as people lockdown, quarantining infected individuals and their family members, canceling public transportation, exit controls, travel and contact restrictions, curfews, school closures, and requiring people to wear mouth and nose masks.2–4 The healthcare sector has undergone dramatic changes as well to cope with the current needs, with the major impact of this social and health crisis on patients with chronic diseases.5 Although there is no evidence that patients with Parkinson’s disease (PD) have a higher risk for contracting COVID-19 or have worse outcomes,6,7 the impact of stress, self-isolation, depression, and anxiety, as well as the consequences of the health system restrictions and prolonged immobility because of the lockdown may have several short-term and long-term adverse consequences for people with PD, such as worsening of motor function and stress-related psychiatric symptoms, such as anxiety and depressive mood.8–12

The main objective of this study was to know how the COVID-19 pandemic has affected Spanish patients with PD based on data from a sample of patients interviewed through an anonymous and voluntary online survey.

Patients and Methods

This is a descriptive, observational, cross-sectional study with a type-anonymous survey of patients with PD. A survey with 95 questions structured in three parts was developed. Part I (PD) included questions 1–61 related to the following categories: sociodemographic variables, variables related to PD, variables related to comorbidities, lifestyle, treatment, quality of life, and independence. Part II (COVID-19) included questions 62–89 that focused on knowledge about the COVID-19 crisis, COVID-19, and impact of the COVID-19 pandemic. Part III (caregiver) included questions 90–95 about the role and burden of the caregiver. In addition, the participants had a free field to leave comments at the end of the survey. The time it took to answer the survey was between 10 and 15 minutes.
The survey was in Spanish in electronic format. Participation was voluntary and anonymous, so that anyone who deemed it appropriate could participate. In the questionnaire it was clear that the participant must have PD or be the caregiver or a family member of a patient with PD who was currently alive or who had died during the pandemic (since March 2020), with the data collected referring to their sick family member (except Part III). The study was launched on 11 May 2020 and disseminated on social networks and different media. Responses were collected from 11 May 2020 to 20 July 2020. It was approved by the regional ethics committee from Galicia. Data were processed using SPSS 20.0 (Armonk, NY) for Windows. The $P$ value was considered significant at <0.05.

Results

Of a total of 570 questionnaires received, 568 (99.6%) were considered valid for the analysis. A total of 327 (57.6%) surveys were answered by patients with PD, 238 (41.9%) by caregivers, and 3 (0.5%) by a relative of a patient with PD who had died. Responses from 49 provinces in Spain were received, with 46.7% during the first 3 days. Mean age of patients was 63.5 ± 12.5 years (range, 30–92 years), and 53% (n = 301) were female. Sociodemographic data are shown in Table 1.

Mean disease duration was 8.4 ± 5.6 (range, 1–30) years. More than half of the patients suffered from tremor, rigidity, falls, motor fluctuations, dyskinesias, anxiety, depression, and pain, and about one in three presented with cognitive problems and behavioral disorders (Table 2, all patients). Symptoms related to PD and comorbidities are listed in Table 2.

Table S1 shows the data related to COVID-19. A total of 553 patients (97.4%) were aware of the COVID-19 pandemic, and 68.8% were concerned about it; 95.6% took preventive measures: 86.8% frequent hand washing, 86.6% wearing a mask, 86.3% rigorous confinement, 80.1% social distancing, and 41.4% use of gloves. A total of 484 patients (85.2%) had no contact with cases of COVID-19, and only 15 (2.6%) had confirmed COVID-19. Out of 15 patients who had COVID-19, 5 (33.3%) were hospitalized (1 in the intensive care unit [ICU]), but none of them died. Although up to 72.7% remained active during confinement, 65.7% perceived a worsening of their symptoms: bradykinesia 47.7%, sleep problems 41.4%, rigidity 40.7%, gait disturbances 34.5%, anxiety 31.3%, pain 28.5%, fatigue 28.3%, depression 27.6%, tremor 20.8%, and appetite disorders 13.2%. In patients with PD, the global subjective negative impact of the COVID-19 pandemic on a scale from 0 (none) to 10 (maximum) was 6.6 ± 2.4 (range, 0–10), with 60% of the scores between 7 and 10. There were no differences about the impact of the COVID-19 pandemic regarding age and sex.

With regard to the caregiver (n = 326 for this analysis), 63.5% of the patients had a principal caregiver (mean age, 60.8 ± 13.3 years [21–89]; 75.1% female): 195 a family member (71.9% spouse; 23.7% a son and/or daughter) and 12 a professional caregiver. In caregivers, the global subjective negative impact of the COVID-19 pandemic from 0 to 10 was 6.9 ± 2.5 (range, 0–10), with 64.7% of the scores between 7 and 10.

### Table 1. Sociodemographic data of the sample (N = 568)

| Sociodemographic variables | N = 568 |
|---------------------------|---------|
| Age, yr                   | 63.5 ± 12.5 (30–92) |
| Female                    | 53.0%   |
| Disease duration, yr      | 8.4 ± 5.6 (1–30)   |
| Race                      |         |
| Caucasian                 | 97.2%   |
| Black                     | 0.5%    |
| Asian                     | 0.4%    |
| Other                     | 1.9%    |
| Level of education        |         |
| Primary                   | 31.2%   |
| Secondary                 | 26.9%   |
| University                | 41.9%   |
| Marital status            |         |
| Married                   | 72.7%   |
| Single                    | 9.5%    |
| Widower                   | 9.2%    |
| Divorced                  | 6.5%    |
| Other                     | 2.1%    |
| Living at home            |         |
| With spouse               | 43.7%   |
| With spouse and son and/or daughter | 30.1% |
| With a son and/or daughter| 6.0%    |
| Alone                     | 8.6%    |
| Other                     | 11.6%   |
| Habitat                   |         |
| Rural (<5000 habitants)   | 13.5%   |
| Semirural (5000–20,000 habitants) | 14.1% |
| Urban (>20,000 habitants) | 72.4%   |
| Work activity             |         |
| No                        | 82.7%   |
| Yes                       | 17.3%   |
| Pension and/or economy support | 72.7% |
| Yes                       | 27.3%   |
| No                        |         |
| Degree of independence for activities of daily living | |
| Completely independent    | 34.2%   |
| Help only for a few things| 43.0%   |
| Dependent                 | 21.8%   |
| Unknown                   | 1%      |
| Self-perceived quality of life |         |
| Very good                 | 8.3%    |
| Good                      | 37.1%   |
| Regular                   | 39.8%   |
| Bad                       | 11.4%   |
| Very bad                  | 2.5%    |
| Unknown                   | 0.9%    |

The results represent percentages or mean ± standard deviation.
When patients with PD who had COVID-19 were compared with patients who did not have the infection, none of the patients who had COVID-19 had hallucinations compared with 23.4% of those who did not have the infection (Table 2, patients with COVID-19 vs patients without COVID-19; \( P = 0.025 \)). Motor fluctuations (61% vs 35.7%), dementia (16.2% vs 6.7%), and behavioral disorders (33.6% vs 15.4%) were about double in patients who did not have COVID-19 than in those who had it (a trend toward significance). In general, cardiovascular risk factors and cardiovascular diseases were more frequent in patients who had COVID-19 compared with those who did not have the infection. The difference was significant in the case of dyslipidemia (64.3% vs 24.1%; \( P = 0.002 \)). However, none the patients who had COVID-19 suffered from

### TABLE 2. Symptoms related to PD and other comorbidities (N = 568)

|                          | Patients with COVID-19 (n = 15) | Non-COVID-19 patients (n = 553) | All patients (N = 568) | \( P \) (patients with COVID-19 vs non-COVID-19 patients) |
|--------------------------|---------------------------------|---------------------------------|------------------------|---------------------------------------------------------|
| Age (yr)                 | 65.6 ± 9.4                      | 63.5 ± 12.6                     | 63.5 ± 12.5            | 0.520                                                   |
| Females (%)              | 52.9                            | 53.3                            | 53                     | 0.593                                                   |
| Disease duration (yr)    | 6.8 ± 4.9                       | 8.5 ± 5.5                       | 8.4 ± 5.6              | 0.246                                                   |
| PD symptoms (%)          |                                 |                                 |                        |                                                         |
| Predominant hemibody     |                                 |                                 |                        |                                                         |
| Right                    | 40                              | 41.6                            | 41.6                   | 0.805                                                   |
| Left                     | 46.7                            | 37.4                            | 37.7                   |                                                         |
| Symmetric                | 13.3                            | 20.6                            | 20.4                   |                                                         |
| Tremor                   | 73.3                            | 55.1                            | 54.9                   | 0.127                                                   |
| Rigidity                 |                                 |                                 |                        |                                                         |
| Yes, continuously        | 33.4                            | 41.4                            | 41.1                   | 0.676                                                   |
| Yes, but occasionally    | 53.3                            | 50.7                            | 50.8                   |                                                         |
| Motor fluctuations       | 35.7                            | 61                              | 60.4                   | 0.052                                                   |
| Dyskinesia               | 53.3                            | 55.9                            | 55.9                   | 0.521                                                   |
| Falls                    |                                 |                                 |                        |                                                         |
| Yes, often               | 0                               | 17.8                            | 17.3                   | 0.193                                                   |
| Yes, but rarely          | 53.3                            | 41.3                            | 41.1                   |                                                         |
| Bad mood/depression      | 57.1                            | 65.6                            | 65.4                   | 0.346                                                   |
| Anxiety                  | 60                              | 65.8                            | 65.6                   | 0.414                                                   |
| Pain                     |                                 |                                 |                        |                                                         |
| Yes, every day           | 26.7                            | 50.4                            | 49.7                   | 0.102                                                   |
| Yes, but occasionally    | 60                              | 33.9                            | 34.6                   |                                                         |
| Cognitive problems       | 38.5                            | 36.2                            | 36.2                   | 0.538                                                   |
| Dementia                 | 6.7                             | 16.2                            | 15.9                   | 0.280                                                   |
| Hallucinations           | 0                               | 23.4                            | 22.8                   | 0.025                                                   |
| Behavioral disorders     | 15.4                            | 33.6                            | 31.5                   | 0.139                                                   |
| Comorbidities (%)        |                                 |                                 |                        |                                                         |
| Arterial hypertension    | 26.7                            | 24.3                            | 24.4                   | 0.519                                                   |
| Diabetes mellitus        | 20                              | 9.7                             | 10                     | 0.181                                                   |
| Dyslipidemia             | 64.3                            | 24.1                            | 25.1                   | 0.002                                                   |
| Ischemic cardiopathy     | 13.3                            | 6.9                             | 7                      | 0.285                                                   |
| Valvular cardiopathy     | 6.7                             | 4.9                             | 4.9                    | 0.534                                                   |
| Cardiac arrhythmia       | 20                              | 12.7                            | 12.9                   | 0.305                                                   |
| Cardiac insufficiency    | 6.7                             | 4.2                             | 4.3                    | 0.488                                                   |
| Pulmonary disease        | 14.3                            | 9.4                             | 9.5                    | 0.391                                                   |
| Any other severe disease |                                 |                                 |                        | 0.311                                                   |
| Oncological disease      | 0                               | 3.1                             | 3.1                    |                                                         |
| Rheumatic disease        | 0                               | 11.7                            | 11.5                   |                                                         |
| Another disabling disease| 0                               | 8.2                             | 8                      |                                                         |
| Smoking                  | 6.7                             | 8.3                             | 8.3                    | 0.642                                                   |
| Complementary therapies (%)|                                 |                                 |                        |                                                         |
| PD association           | 60                              | 56.6                            | 56.3                   | 0.796                                                   |
| Physiotherapy            | 66.7                            | 58.7                            | 58.9                   | 0.368                                                   |
| Exercise                 | 78.6                            | 64.7                            | 65                     | 0.217                                                   |
| Speech therapy           | 33.3                            | 47.4                            | 47                     | 0.210                                                   |
| Cognitive stimulation    | 33.3                            | 57.3                            | 56.7                   | 0.057                                                   |

The results represent mean ± standard deviation or percentage (%). Chi-square and Mann-Whitney-Wilcoxon test were applied. Positive responses are shown. In the case of unknown, the percentage was low (from 0.4% for smoking to 4.9% for behavioral disorders).

Abbreviations: PD, Parkinson’s disease; COVID-19, coronavirus disease 2019. A significance value of \( P < 0.05 \) is expressed in bold.
Discussion

This study, the largest one conducted to determine the impact of COVID-19 on patients with PD, found that most patients were aware of the COVID-19 pandemic, were fearful of the risk of contagion, and met prevention standards in a remarkably responsible way. Furthermore, more than half of the patients answered that their PD symptoms had worsened during confinement. Although the study was not designed to determine the prevalence of COVID-19, the data suggest that the percentage of patients affected by the infection could be rather low.

Three studies using a similar methodology, a semistructured interview directed at patients and/or caregivers, have been published to date. Prasad et al. reported that 100% of 100 patients and 100 caregivers were aware of the pandemic in a study conducted in India. Of 99 patients with PD from Germany, all but 3 patients (missing data) answered being informed, more than half well or very well, and even 51% with too much information about the virus. As in previous studies, the most widely used medium for receiving information was television. However, Spanish patients with PD who participated in this study were more fearful of contracting COVID-19, up to 42%, compared with less than 10% or 28% in other studies. A consequence of this fear could be the high degree of compliance with prevention standards according to the responses obtained, with nearly 90% complying with rigorous containment, hand washing, and use of a mask.

An important observation is that up to 66% of the patients perceived a worsening of their symptoms during confinement, and up to 70% answered that the pandemic had had a negative impact on them. Bradykinesia, sleep problems, rigidity, and gait disturbances were the symptoms that most frequently worsened, probably related to decreased physical activity and psychological stress. Our results are in line with a previous study conducted in Italy, which, like Spain, has been one of the countries most punished by COVID-19. The closure of patient associations and/or rheumatic disease. Interestingly, none of the patients receiving amantadine (n = 82) suffered from COVID-19 infection (P = 0.064).

Oncological and/or rheumatic disease. Interestingly, none of the patients receiving amantadine (n = 82) suffered from COVID-19 infection (P = 0.064).

Acknowledgments: We thank all patients, caregivers, and all persons, companies, and institutions collaborating in this project. We especially thank Fundación Curemos el Parkinson (https://curemoselparkinson.org/), Asociación Parkinson Galicia – Coruña (https://parkinsongaliciacoruña.org/), and Federación Española de Parkinson (https://www.esparkinson.es/).

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsu EB. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924.

2. Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. J Parkinsons Dis 2020;10:351–354.
3. Koo JR, Cook AR, Park M, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. Lancet Infect Dis 2020;10:677–688.

4. Prem K, Liu Y, Russell TW, et al. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. Lancet Public Health 2020;5:261–270.

5. Haybar H, Kazemnia K, Rahim F. Underlying chronic disease and COVID-19 infection: a state-of-the-art review. Jundishapur J Chronic Dis Care 2020;9:e103452.

6. Stoessl AJ, Bhatia KP, Merello M. Movement disorders in the world of COVID-19. Mov Disord Clin Pract 2020;7:355–356.

7. Papa SM, Brundin P, Fung VSC, et al. Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders. Mov Disord Clin Pract 2020;7:357–360.

8. Moro E, Fernandez HH. Adaptive neurology in COVID-19 times. Parkinsonism Relat Disord 2020;30168–1:S1353

9. Prasad S, Holla VV, Neeraja K, et al. Parkinson’s disease during the coronavirus disease (COVID-19) pandemic. Mov Disord 2020;35:1095–1096.

10. Zipprich HM, Teschner U, Witte OW, Schönenberg A, Prell T. Knowledge, attitudes, practices, and burden during the COVID-19 pandemic: in people with Parkinson’s disease in Germany. J Clin Med 2020;9(6):E1643.

11. Schirinzi T, Cerroni R, Di Laazaro G, et al. Self-reported needs of patients with Parkinson’s disease during COVID-19 emergency in Italy. Neurosci Lett 2020;74:1373–1375.

12. Bhidayasiri R, Virameteekul S, Kim JM, Pal PK, Chung SJ. COVID-19: an early review of its global impact and considerations for Parkinson’s disease patient care. J Mov Disord 2020;13:105–114.

13. Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The fear of COVID-19 scale: development and initial validation. Int J Ment Health Addict 2020;1–9.

14. Zach H, Dirkx MF, Pasman JW, Bloem BR, Helmich RC. Cognitive stress reduces the effect of levodopa on Parkinson’s resting tremor. CNS Neurosci Ther 2017;23:209–215.

15. The Michael J. Fox Foundation for Parkinson’s Research. https://www.michaeljfox.org/publication/michael-j-fox-foundation-releases-first-and-largest-data-set-self-reported-outcomes.

16. van der Kolk NM, de Vries NM, Kessels RPC, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: a double-blind, randomised controlled trial. Lancet Neurol 2019;18:998–1008.

17. Srivastav AK, Asir JS. E-rehabilitation: one solution for patients with Parkinson’s disease in COVID-19 era. Parkinsonism Relat Disord 2020;73:128–129.

18. Fasano A, Antonini A, Katzenschlager R, et al. Management of advanced therapies in Parkinson’s disease patients in times of humanitarian crisis: the COVID-19 experience. Mov Disord Clin Pract 2020;7:361–372.

19. Goetz CG, StHBins GT, Luo S. Movement Disorder Society-unified Parkinson’s disease rating scale use in the Covid-19 era. Mov Disord 2020;35(6):911.

20. Miocinovic S, Ostrem JL, Okun MS, et al. Recommendations for deep brain stimulation device management during a pandemic. J Parkinsons Dis 2020;10:903–910.

21. Cubo E, Hassan A, Bloem BR, Mari Z, MDS-Telemedicine Study Group. Implementation of telemedicine for urgent and ongoing healthcare for patients with Parkinson’s disease during the COVID-19 pandemic: new expectations for the future. J Parkinsons Dis 2020;10:911–913.

22. Devigili G, Eleopra R, Rinaldo S, Lanteri P. Lessons from the present: intraoperative neurophysiological monitoring organization during the COVID-19 pandemic in Lombardy, northern Italy. Clin Neurophysiol 2020;131:2056–2058.

23. Dang S, Penney LS, Trivedi R, et al. Caring for caregivers during COVID-19. J Am Geriatr Soc 2020; (epub head of print). https://doi.org/10.1111/jgs.16726.

24. Fasano A, Cereda F, Barichella M, et al. COVID-19 in Parkinson’s disease patients living in Lombardy, Italy. Mov Disord 2020;35:1089–1093.

25. Gilia R, Bonvegna S, Straccia G, et al. Effects of COVID-19 on Parkinson’s disease clinical features: a community-based case-control study. Mov Disord 2020;35:1287–1292.

26. Tipton PW, Wszolek ZK. What can Parkinson’s disease teach us about COVID-19? Neurol Neurochir Pol 2020;54:204–206.

27. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;m1091:368.

28. Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle risk factors for cardiovascular disease in relation to COVID-19 hospitalization: a community-based cohort study of 387,109 adults in UK. medRxiv 2020. https://doi.org/10.1101/2020.03.09.20096438.

29. Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID-19 treatment. Int J Antimicrob Agents 2020;55:106004.

30. Rejdak K, Grieb P. Adamanteranes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord 2020;42:102163.

**Supporting Data**

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.